WuXi AppTec has been removed from the Pentagon’s Section 1260H list of Chinese military companies, after the Department of War complied with an August 7, 2026 court ordered preliminary injunction. The removal notice was made public on November 9 and published in the Federal Register on November 10. WuXi, one of the largest contract research and manufacturing organizations serving United States biopharma, was added to the list on June 8, 2026 and sued three days later. The delisting lifts the bar on Pentagon contracting with the company, but the relief is preliminary, the case on the merits is still pending, and WuXi could still be designated under the separate BIOSECURE Act process, whose initial list of biotechnology companies of concern is due from the Office of Management and Budget by December 18, 2026.
A congressional advisory body, the US-China Economic and Security Review Commission, used its annual report to warn that China is gaining a competitive advantage in biopharmaceuticals, with Western firms paying large upfront fees to license Chinese drugs. Commission member Leland Miller told a hearing the two countries are on a trajectory where China could become an innovation hub capable of replacing the United States. The commission also warned of United States dependence on China for raw pharmaceutical ingredients, including the blood thinner heparin and essential hospital antibiotics, and recommended a diversification programme built on cooperation with India, with multiyear government purchasing commitments for essential medicines made with trusted partner ingredients.
Separately, the Treasury Department’s October 22, 2026 proposed rules under the COINS Act would prohibit certain United States investments in Chinese biotechnology, and a pending Biotech Investment National Security Act would extend screening to licensing deals. The perimeter is therefore still being built in layers, procurement, outbound investment and inbound review, even as the industry’s dependence on Chinese capacity continues to grow.